As a result, thioredoxin reductases have been identified as anti-cancer targets and small molecules inhibitors of thioredoxin reductases (such as organoselenium compounds) are currently used in the treatment of prostate cancer [30], [31]. The gene discussed is PRDX5; the disease is prostate carcinoma.